$JNCE News

Last published 3y ago

3y agoJNCEJounce Therapeutics Announces Closing of Tender OfferGlobeNewswireCAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies
3y agoJNCETermination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plcGlobeNewswireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
3y agoJNCEJounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value RightsGlobeNewswireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass.,
3y agoJNCEJounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian CancerGlobeNewswireCAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers,
3y agoJNCEJounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesGlobeNewswireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE,
3y agoBRMK FOCS JNCE ROCCMoore Kuehn Encourages ROCC, JNCE, BRMK, and FOCS Investors to Contact Law FirmPR NewswireNEW YORK, March 1, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
3y agoINDT JNCE PTRS VBLTMoore Kuehn Encourages PTRS, VBLT, INDT, and JNCE Investors to Contact Law FirmGlobeNewswireNEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
3y agoJNCERedx and Jounce Announce Recommended Business CombinationGlobeNewswireCombined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease RXC007, a next-generation
3y agoJNCEJounce Therapeutics Announces RestructuringGlobeNewswireCAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers,
3y agoGILD JNCEGilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce TherapeuticsGlobeNewswireFOSTER CITY, Calif. and CAMBRIDGE, Mass., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (NASDAQ:GILD) and Jounce Therapeutics, Inc. (NASDAQ:JNCE) amended their existing license agreement for GS-1811 (formerly
3y agoGILD JNCEGilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce TherapeuticsBusiness Wire-- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors -- Gilead Sciences, Inc. (NASDAQ:GILD) and Jounce Therapeutics, Inc.
3y agoJNCEJounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual CongressGlobeNewswire- INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with pimivalimab (pimi) - - Patient with advanced biliary tract cancer who failed multiple lines of
4y agoJNCEJounce Therapeutics Reports Third Quarter 2022 Financial ResultsGlobeNewswire- INNATE trial of JTX-8064 +/- pimivalimab Phase 1 Dose Escalation data at ESMO-IO Annual Congress - - SELECT randomized trial of pimivalimab +/- vopratelimab phase 2 data at ESMO-IO Annual Congress - - Two preclinical
4y agoGILD JNCEJounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc.GlobeNewswireCAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers,
4y agoJNCEJounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022GlobeNewswireCAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers,
4y agoJNCEJounce Therapeutics to Present Multiple Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting and the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) Annual CongressGlobeNewswire- Two preclinical posters highlighting the JTX-1484 program and LILRB family at SITC 2022 - - Two clinical posters highlighting data from the SELECT and INNATE trials at ESMO-IO - CAMBRIDGE, Mass., Oct. 20, 2022
4y agoJNCEJounce Therapeutics to Participate in the Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company mana
4y agoJNCEJounce Therapeutics Reports Results from Phase 2 Randomized SELECT Trial Testing 2 Different Doses of Vopratelimab in TISvopra Biomarker-Selected PatientsGlobeNewswire- SELECT trial of vopratelimab in combination with pimivalimab versus pimivalimab alone did not meet its primary endpoint of mean tumor change averaged over 9 and 18 weeks - - Encouraging trends in improved mean tumor change over 9 and 18 weeks, and
4y agoJNCEJounce Therapeutics Reports Second Quarter 2022 Financial ResultsGlobeNewswire- INNATE trial of JTX-8064 +/- pimivalimab on track to present preliminary data on at least 80 Phase 2 patients across multiple cohorts by year end - - Patient enrollment complete in the randomized, Phase 2 SELECT trial of vopratelimab in combinatio
4y agoJNCEJounce Therapeutics to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022GlobeNewswireCAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will repor
4y agoJNCEJounce Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce managem
4y agoJNCEJounce Therapeutics Reports First Quarter 2022 Financial ResultsGlobeNewswire- Two combination cohorts met initial response criteria for continued expansion in INNATE trial of JTX-8064; on track to present data on at least 60 Phase 2 patients across multiple cohorts in 2H2022 - - Target enrollment achieved in SELECT tria
4y agoJNCEJounce Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022GlobeNewswireCAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will repo
4y agoJNCEJounce Therapeutics to Participate in Raymond James LILRB/ILT Symposium: Deep Dive into "Myeloid Checkpoint" Therapeutics in CancerGlobeNewswireCAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce manag
4y agoJNCEJounce Therapeutics Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewswire- Continued execution on two proof-of-concept clinical trials for JTX-8064 and Vopratelimab, INNATE and SELECT, with clinical data on track for 2022 - - JTX-1484, a new antagonist antibody targeting LILRB4, enters IND-enabling activities representin
4y agoJNCEJounce Therapeutics to Participate in Cowen & Co. 42nd Annual Health Care ConferenceGlobeNewswireCAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce manage
4y agoJNCEJounce Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Wednesday, March 2, 2022GlobeNewswireCAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will repor
4y agoJNCEJounce Therapeutics to Present at Upcoming Investor Conferences in JanuaryGlobeNewswireCAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company manag
5y agoJNCEJounce Therapeutics to Present at Upcoming Investor Conferences in NovemberGlobeNewswireCAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company manag
5y agoJNCEJounce Therapeutics, inc (JNCE) Q3 2021 Earnings Call TranscriptEarnings Call TranscriptsJNCE earnings call for the period ending September 30, 2021.
5y agoJNCEJounce Therapeutics Reports Third Quarter 2021 Financial ResultsGlobeNewswire- Commenced enrollment in tumor-specific monotherapy and pimivalimab combination expansion cohorts of INNATE trial of JTX-8064 - - Ended the quarter with $249.0 million in cash, cash equivalents and investments - - Company to host conference call a
5y agoJNCEJounce Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, 2021GlobeNewswireCAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will repor
5y agoJNCEJounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid TumorsGlobeNewswire- Enrollment initiated in tumor-specific monotherapy and pimivalimab combination expansion cohorts – - Monotherapy and pimivalimab combination dose escalation enrollment completed - CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Jounce Th
5y agoAIM BKYI DAL JNCE+1Thinking about buying stock in BIO-key, AIM ImmunoTech, Jounce Therapeutics, Delta Air Lines, or Rekor Systems?PR NewswireNEW YORK, Sept. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BKYI, AIM, JNCE, DAL, and REKR. T
5y agoJNCEJounce Therapeutics Appoints Jigar Raythatha to its Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment o
5y agoJNCEJounce Therapeutics to Present at Upcoming Investor Conferences in SeptemberGlobeNewswireCAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company mana
5y agoJNCEJounce Therapeutics Reports Second Quarter 2021 Financial ResultsGlobeNewswire- INNATE monotherapy dose escalation enrollment completed and target dose selected, on track to initiate indication specific expansions in third quarter 2021- - Announced two additional LILRB family targets as potential future development candidates
5y agoJNCEJounce Therapeutics, inc (JNCE) Q2 2021 Earnings Call TranscriptEarnings Call TranscriptsJNCE earnings call for the period ending June 30, 2021.
5y agoJNCEJounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Conference Call on Thursday, August 5, 2021GlobeNewswireCAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will repor
5y agoJNCEJounce Therapeutics to Participate in William Blair's Biotech Focus ConferenceGlobeNewswireCAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Dmitri Wieder
5y agoJNCEJounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, and Provides a Portfolio Update at 2021 R&D DayGlobeNewswire- INNATE study rapidly advancing; updates to be provided on enrollment status and receptor occupancy; expansion cohorts expected to open for enrollment in third quarter of 2021- - Introduction of two additional LILRB family targets as potential develo
5y agoJNCEJounce Therapeutics to Host Virtual R&D Day on June 23, 2021GlobeNewswireCAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it will host a vir
5y agoGILD JNCEJounce Therapeutics Achieves First Milestone in Exclusive License Agreement with Gilead Sciences and FDA Clearance of Investigational New Drug Application for Anti-CCR8 AntibodyGlobeNewswireCAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the U.S. Food and
5y agoJNCEJounce Therapeutics to Participate in Fireside Chat at the Raymond James Human Health Innovation ConferenceGlobeNewswireCAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murra
5y agoJNCEJounce Therapeutics Presents Trial in Progress Posters on the INNATE and SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual MeetingGlobeNewswire- INNATE trial to include proof-of-concept expansion cohorts in lung, renal, head and neck, triple negative breast, cutaneous squamous cell, and ovarian cancers and soft tissue sarcomas - - SELECT TISvopra positivity rate for patient selection in-li
5y agoJNCEJounce Therapeutics, Inc. (JNCE) Q1 2021 Earnings Call TranscriptEarnings Call TranscriptsJNCE earnings call for the period ending March 31, 2021.
5y agoJNCEJounce Therapeutics Reports First Quarter 2021 Financial ResultsGlobeNewswire- Enrollment on track in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the biomarker selected Phase 2 SELECT trial of Vopratelimab in combination with Pimivalimab - - Ended the quarter with $271.3 million in cash, cash equivalents an
5y agoJNCEJounce Therapeutics, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 4, 2021 / Jounce Therapeutics, Inc. (NASDAQ:JNCE) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 4, 2021 at 8:00 AM Eastern Time. To listen to the event live or acces
5y agoJNCEJounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual MeetingGlobeNewswireCAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that two trial in
5y agoJNCEJounce Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on Tuesday, May 4, 2021GlobeNewswireCAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will repo